Proton-pump inhibitor use is associated with lower urinary magnesium excretion

Nephrology

Volumn 19, Issue 12, 2014, Pages 798-801

  William, Jeffrey H ^a   Nelson, Rachel ^a   Hayman, Najwah ^a   Mukamal, Kenneth J ^a   Danziger, John ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

electrolytes; hypomagnesaemia; magnesium; proton pump inhibitors

Indexed keywords

DIURETIC AGENT; MAGNESIUM; PROTON PUMP INHIBITOR; BIOLOGICAL MARKER;

ADULT; ARTICLE; CONTROLLED STUDY; DIETARY INTAKE; DISEASE ASSOCIATION; DRUG USE; FEMALE; HUMAN; HYPOMAGNESEMIA; MAGNESIUM EXCRETION; MAGNESIUM URINE LEVEL; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NEPHROLITHIASIS; PRIORITY JOURNAL; URINALYSIS; URINARY EXCRETION; AGED; DOWN REGULATION; DRUG EFFECTS; KIDNEY; METABOLISM; MIDDLE AGED; UNITED STATES; URINE;

ADULT; AGED; BIOMARKERS; BOSTON; DOWN-REGULATION; FEMALE; HUMANS; KIDNEY; MAGNESIUM; MALE; MIDDLE AGED; PROTON PUMP INHIBITORS; RENAL ELIMINATION;

EID: 84929623116     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/nep.12330     Document Type: Article

References (18)

1. Herzig SJ, Howell MD, Ngo LH, Marcantonio ER,. Acid-suppressive medication use and the risk for hospital-acquired pneumonia. JAMA 2009; 301: 2120-2128.
2. Ray S, Delaney M, Muller AF,. Proton pump inhibitors and acute interstitial nephritis. BMJ 2010; 341: c4412.
3. Sierra F, Suarez M, Rey M, Vela MF,. Systematic review: Proton pump inhibitor-associated acute interstitial nephritis. Aliment. Pharmacol. Ther. 2007; 26: 545-553.
4. Cunningham R, Dale B, Undy B, Gaunt N,. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J. Hosp. Infect. 2003; 54: 243-245.
5. Howell MD, Novack V, Grgurich P, et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch. Intern. Med. 2010; 170: 784-790.
6. Faulhaber GA, Furlanetto TW,. Could magnesium depletion play a role on fracture risk in PPI users? Arch. Intern. Med. 2010; 170: 1776.
7. Abraham NS, Hlatky MA, Antman EM, et al. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: A focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. A report of the American College of Cardiology Foundation Task Force on expert consensus documents. J. Am. Coll. Cardiol. 2010; 56: 2051-2066.
8. Mackay JD, Bladon PT,. Hypomagnesaemia due to proton-pump inhibitor therapy: A clinical case series. QJM 2010; 103: 387-395.
9. Hoorn EJ, van der Hoek J, de Man RA, Kuipers EJ, Bolwerk C, Zietse R,. A case series of proton pump inhibitor-induced hypomagnesemia. Am. J. Kidney Dis. 2010; 56: 112-116.
10. Kuipers MT, Thang HD, Arntzenius AB,. Hypomagnesaemia due to use of proton pump inhibitors-a review. Neth. J. Med. 2009; 67: 169-172.
11. Epstein M, McGrath S, Law F,. Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N. Engl. J. Med. 2006; 355: 1834-1836.
12. Shabajee N, Lamb EJ, Sturgess I, Sumathipala RW,. Omeprazole and refractory hypomagnesaemia. BMJ 2008; 337: a425.
13. US Department of Health and Human Services, Food and Drug Safety Communication. Proton Pump Inhibitor drugs (PPIs): Drug safety communication-low magnesium levels can be associated with long-term use. [Cited 3 Mar 2011.] Available from URL: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm245275.htm
14. Danziger J, William JH, Scott DJ, et al. Proton-pump inhibitor use is associated with low serum magnesium concentrations. Kidney Int. 2013; 83: 692-699.
15. Koulouridis I, Alfayez M, Tighiouart H, et al. Out-of-hospital use of proton pump inhibitors and hypomagnesemia at hospital admission: A nested case-control study. Am. J. Kidney Dis. 2013; 62: 730-737.
16. Thongon N, Krishnamra N,. Omeprazole decreases magnesium transport across Caco-2 monolayers. World J. Gastroenterol. 2011; 17: 1574-1583.
17. Bai JP, Hausman E, Lionberger R, Zhang X,. Modeling and simulation of the effect of proton pump inhibitors on magnesium homeostasis. 1. Oral absorption of magnesium. Mol. Pharm. 2012; 9: 3495-3505.
18. Barbagallo M, Dominguez LJ,. Magnesium metabolism in type 2 diabetes mellitus, metabolic syndrome and insulin resistance. Arch. Biochem. Biophys. 2007; 458: 40-47.